NCT06679985Phase 2Active not recruiting

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Study sponsor: Coherus Oncology, Inc. · CHRS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-09Estimated

Enrollment · participants72Estimated

Source updated2026-07-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-13 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source

Study details

Conditions studied

Hepatocellular Carcinoma

Treatments or interventions studied

CasdozokitugDrugAlso known as CHS-388
ToripalimabDrug
BevacizumabDrug

Primary outcomes · main study measures

measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs); timeFrame: From date of first dose to 90 days after date of last dose (Up to approximately 27 months); measure: Objective Response Rate (ORR) by Investigator Review According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; timeFrame: Up to approximately 2 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history